×

This article on Epainassist.com has been reviewed by a medical professional, as well as checked for facts, to assure the readers the best possible accuracy.

We follow a strict editorial policy and we have a zero-tolerance policy regarding any level of plagiarism. Our articles are resourced from reputable online pages. This article may contains scientific references. The numbers in the parentheses (1, 2, 3) are clickable links to peer-reviewed scientific papers.

The feedback link “Was this Article Helpful” on this page can be used to report content that is not accurate, up-to-date or questionable in any manner.

This article does not provide medical advice.

1

Neuroleptic vs. Serotonin Syndrome : A Comprehensive Guide

Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome are two distinct but potentially serious medical conditions associated with the use of certain medications. Read on to find out more about these two conditions.

Neuroleptic Malignant Syndrome (NMS)

Neuroleptic Malignant Syndrome (NMS) is a rare but potentially life-threatening neurological disorder that can occur as a side effect of certain antipsychotic medications. It is characterized by symptoms such as severe muscle rigidity, high fever, altered mental status, and autonomic dysregulation (irregularities in functions controlled by the autonomic nervous system like blood pressure, heart rate, and sweating). NMS requires prompt medical attention and discontinuation of the offending medication.(1)

Serotonin Syndrome

Serotonin Syndrome is a potentially life-threatening condition that can occur due to excessive serotonin levels in the brain. This often results from the use of certain medications that affect serotonin levels, such as antidepressants, particularly when taken in high doses or in combination with other drugs that also increase serotonin levels. Serotonin Syndrome is characterized by symptoms like agitation, high body temperature, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, it can lead to seizures and even death if not treated promptly.(2)

Comparing The Causes of Neuroleptic Malignant Syndrome and Serotonin Syndrome

Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome have different underlying causes:

Neuroleptic Malignant Syndrome (NMS):

  • NMS is primarily caused by the use of antipsychotic medications, also known as neuroleptics. These drugs block dopamine receptors in the brain, which can lead to disruption in the normal functioning of the central nervous system.(3)
  • It is believed that NMS arises from an imbalance between dopamine and other neurotransmitters in the brain. The exact mechanism is not fully understood, but it is thought that the blockade of dopamine receptors can lead to a cascade of events causing the characteristic symptoms of NMS.

Serotonin Syndrome:

  • Serotonin Syndrome is caused by an excess of serotonin, a neurotransmitter, in the brain. This can occur due to various factors, but it is most commonly associated with the use of certain medications that increase serotonin levels.
  • The syndrome often results from the use of drugs that affect serotonin levels, such as certain antidepressants (particularly those in the selective serotonin reuptake inhibitor, or SSRI, class) and other medications like certain pain relievers (e.g., tramadol) or illicit substances (e.g., MDMA, commonly known as “ecstasy”). When these substances are used in high doses or in combination, they can lead to an excessive accumulation of serotonin in the brain, causing the symptoms of serotonin syndrome. This is due to overstimulation of serotonin receptors in the central nervous system. (4)

Comparing The Symptoms of Neuroleptic Malignant Syndrome and Serotonin Syndrome

The symptoms of Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome can be similar in some aspects, which can sometimes make it challenging to differentiate between the two. Both conditions can involve changes in mental status, muscle rigidity, and autonomic dysregulation. However, there are also some distinct differences. Here are the major symptoms of both these conditions.

Neuroleptic Malignant Syndrome (NMS): (5)   

  1. Muscle Rigidity:

  • Severe muscle stiffness or rigidity, often described as “lead pipe” rigidity.
  • Can affect any muscle group, including limbs, neck, and trunk.
  1. Hyperthermia:

  • High fever, often above 38°C (100.4°F) and sometimes much higher.
  • Rapid and abrupt onset.
  1. Altered Mental Status:

  • Changes in consciousness and cognition.
  • Can vary from confusion and disorientation to agitation and catatonia (a state of immobility and unresponsiveness).
  1. Autonomic Dysregulation:

  • Irregularities in functions controlled by the autonomic nervous system.
  • Examples:
    • Blood Pressure: Fluctuations, which can be extremely high or low.
    • Heart Rate: Tachycardia (rapid heart rate) is common.
    • Sweating: Profuse sweating.
    • Increased respiratory rate.
  1. Tremors:

  • Involuntary trembling or shaking.
  • Can range from mild to severe.
  1. Inappropriate Behavior: Behaviors that are unusual or inappropriate for the situation.
  2. Dysphagia: Difficulty swallowing.
  3. Increased Creatine Kinase (CK) Levels: Elevated levels of CK, indicating muscle damage.

Serotonin Syndrome: (6)   

  1. Agitation and Restlessness:

Increased physical and mental activity, often accompanied by anxiety.

  1. Altered Mental Status:

  • Changes in consciousness and cognition, similar to NMS.
  • Can include confusion, hallucinations, and delirium.
  1. Autonomic Dysregulation:

  • Irregularities in autonomic nervous system functions.
  • Examples:
    • Elevated Heart Rate and Blood Pressure.
    • Dilated Pupils.
    • Sweating Profusely.
  1. Hyperthermia: Elevated body temperature, though usually not as high as in NMS.
  2. Hyperreflexia: Overactive or exaggerated reflexes.
  3. Tremors and Muscle Twitching: Involuntary muscle movements.
  4. Diarrhea and GI Distress: Gastrointestinal symptoms like diarrhea, nausea, and vomiting.
  5. Increased Creatine Kinase (CK) Levels: Elevated levels of CK, similar to NMS.

Comparing Neuroleptic Malignant Syndrome and Serotonin Syndrome: Similarities and Differences

Similarities:

  • Neurological Disorders: Both NMS and Serotonin Syndrome are neurological disorders associated with alterations in neurotransmitter activity in the brain.
  • Medication-Induced: Both conditions are typically triggered by the use of medications, although the classes of medications differ.
  • Altered Mental Status: Both syndromes can lead to changes in consciousness and cognition, ranging from confusion to delirium.
  • Autonomic Dysregulation: Irregularities in functions controlled by the autonomic nervous system are present in both conditions. This includes changes in heart rate, blood pressure, and sweating.
  • Hyperthermia: Elevated body temperature (hyperthermia) is a characteristic feature in both NMS and Serotonin Syndrome.

Differences:

Neuroleptic Malignant Syndrome (NMS):

  • Associated Medications: NMS is primarily caused by antipsychotic medications (neuroleptics) which block dopamine receptors in the brain.
  • Muscle Rigidity: Prominent Symptom: Severe muscle stiffness or rigidity is a hallmark feature of NMS.
  • Onset: Develops over days to weeks after starting or increasing the dosage of an antipsychotic medication.
  • Tremors: Tremors and muscle twitching are less common.
  • Creatine Kinase (CK) Levels: Elevated levels of CK, indicating muscle damage, are typically seen.

Serotonin Syndrome:

  • Associated Medications: Cause: Serotonin Syndrome arises from an excess of serotonin in the brain, often due to medications that affect serotonin levels (e.g., certain antidepressants, pain relievers).
  • Agitation and Restlessness: Prominent Symptom: Agitation and restlessness are more characteristic of Serotonin Syndrome.
  • Hyperreflexia: Overactive or exaggerated reflexes are a distinguishing feature.
  • Tremors and Muscle Twitching: Tremors and muscle twitching are common in Serotonin Syndrome.
  • Gastrointestinal Symptoms: Symptoms like diarrhea, nausea, and vomiting are often present.
  • Creatine Kinase Levels: Elevated CK levels can also be observed, though less consistently compared to NMS.

Comparing The Treatment of Neuroleptic Malignant Syndrome and Serotonin Syndrome

The treatment approaches for Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome differ due to their distinct underlying causes.

Neuroleptic Malignant Syndrome (NMS): (7) 

  1. Discontinuation of Causative Medication:

  • Critical Step: The first and most crucial step is to immediately stop the administration of the neuroleptic medication that triggered NMS.
  1. Supportive Care:

  • Hospitalization: Patients with NMS typically require hospitalization in an intensive care unit (ICU) or a specialized medical unit for close monitoring.
  • Fluids and Electrolytes: Intravenous fluids may be administered to maintain hydration and correct any electrolyte imbalances.
  • Temperature Management: Active cooling methods may be used to bring down elevated body temperature.
  • Cardiovascular Monitoring: Continuous monitoring of blood pressure, heart rate, and other vital signs is essential.
  1. Pharmacological Interventions:

  • Dantrolene: A muscle relaxant, dantrolene, may be administered to alleviate muscle rigidity.
  • Bromocriptine or Amantadine: These drugs, which affect dopamine receptors, have been used in some cases to help counteract the effects of NMS.
  1. Monitoring and Support:

  • Frequent assessment of the patient’s condition, including neurological status and vital signs, is crucial.
  1. Recovery Period:

  • Recovery from NMS can be slow.

Serotonin Syndrome: (8) 

  1. Discontinuation of Causative Medication:

  • As with NMS, the first step is to cease the use of any medications that are contributing to the development of Serotonin Syndrome.
  1. Supportive Care:

  • Hospitalization: Like NMS, patients with Serotonin Syndrome often require hospitalization for close monitoring.
  • Fluids and Electrolytes: Intravenous fluids may be administered to maintain hydration and address any electrolyte imbalances.
  • Temperature Management: Active cooling methods may be used if hyperthermia is severe.
  • Cardiovascular Monitoring: Continuous monitoring of vital signs is essential.
  1. Pharmacological Interventions:

  • Serotonin Antagonists: In severe cases, medications that block serotonin receptors (such as cyproheptadine) may be used to counteract the effects of excess serotonin.
  1. Monitoring and Support:

  • Frequent assessment of the patient’s condition, including neurological status and vital signs, is crucial.
  1. Recovery Period:

  • With prompt and appropriate treatment, patients with Serotonin Syndrome often recover relatively quickly.

In both cases, early recognition and intervention are critical for a positive outcome.

Conclusion

Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome, though sharing some symptoms, have distinct causes and require different treatments. NMS, linked to antipsychotic drugs, demands discontinuation of the causative medication and intensive care. Serotonin Syndrome, arising from serotonin excess, requires prompt cessation of relevant drugs, supportive measures, and, in severe cases, serotonin antagonists. Early recognition and professional intervention are crucial for optimal outcomes. Always consult a healthcare expert for accurate diagnosis and care.

References:

  1. Levenson, J.L., 1985. Neuroleptic malignant syndrome. The American journal of psychiatry, 142(10), pp.1137-1145.
  2. Volpi-Abadie, J., Kaye, A.M. and Kaye, A.D., 2013. Serotonin syndrome. Ochsner Journal, 13(4), pp.533-540.
  3. Strawn, J.R., Keck Jr, MD, P.E. and Caroff, S.N., 2007. Neuroleptic malignant syndrome. American Journal of Psychiatry, 164(6), pp.870-876.
  4. Sternbach, H., 1991. The serotonin syndrome. Am J Psychiatry, 148(6), pp.705-713.
  5. Adnet, P., Lestavel, P. and Krivosic‐Horber, R., 2000. Neuroleptic malignant syndrome. British journal of anaesthesia, 85(1), pp.129-135.
  6. Martin, T.G., 1996. Serotonin syndrome. Annals of emergency medicine, 28(5), pp.520-526.
  7. Caroff, S.N. and Mann, S.C., 1993. Neuroleptic malignant syndrome. The Medical clinics of North America, 77(1), pp.185-202.
  8. Buckley, N.A., Dawson, A.H. and Isbister, G.K., 2014. Serotonin syndrome. Bmj, 348.
Team PainAssist
Team PainAssist
Written, Edited or Reviewed By: Team PainAssist, Pain Assist Inc. This article does not provide medical advice. See disclaimer
Last Modified On:September 20, 2023

Recent Posts

Related Posts